Journal: Cell Death & Disease

Article Title: HCRP-1 regulates EGFR–AKT–BIM-mediated anoikis resistance and serves as a prognostic marker in human colon cancer

doi: 10.1038/s41419-018-1217-2

Figure Lengend Snippet: a , b HCT116 and SW620 cells were transfected with si-HCRP-1 or control siRNA, and then cells were harvested and submitted to Western blot detection for the protein expression of BIM, FoxO3a, EGFR, AKT, ERK, Mcl-1, Bcl-2, and β-actin. Phosphorylated forms of EGFR, AKT, FoxO3a, and ERK were also detected by western blot with the corresponding antibodies. c–f Cells were treatedwith CHX for 0, 0.5 , 1, and 2 h after transfection with si-HCRP-1 or control siRNA for 48 h, lysates obtained from these cells were submitted to western blot detection for the protein expression of EGFR. Error bars indicate mean ± SD. Every experiment was repeated at least three times. * P < 0.05 vs. siCtrl group

Article Snippet: Antibodies against EGFR (sc-03-G), ERK (sc-271269), and p-ERK (Tyr204, sc-7382) were purchased from Santa Cruz (CA, USA).

Techniques: Transfection, Control, Western Blot, Expressing

Journal:

Article Title: Epiregulin is a potent vascular smooth muscle cell-derived mitogen induced by angiotensin II, endothelin-1, and thrombin

doi:

Figure Lengend Snippet: Recombinant rat epiregulin stimulates EGF receptor activation in cultured RASM cells. Serum-starved RASM cells were either untreated (Control) or stimulated for 5 min with PDGF-BB (50 ng/ml), EGF (100 ng/ml), betacellulin (100 ng/ml), or 2× concentrated conditioned media (CM) obtained from epiregulin or mock-transfected COS-7 cells as indicated. Cell lysates were immunoprecipitated with anti-P-Tyr antibodies, and recovered proteins were resolved by SDS/PAGE. Duplicate gels were immunoblotted with either anti-P-Tyr (A) or anti-EGF receptor (B) antibodies. Anti-P-Tyr-recovered EGF receptors are indicated by the arrow (B). Data are representative of independent experiments performed on two separate occasions.

Article Snippet: Duplicate immunoblots were probed separately with anti-P-Tyr or goat polyclonal antibodies directed against the EGF receptor (SC-03G, Santa Cruz Biotechnology).

Techniques: Recombinant, Activation Assay, Cell Culture, Transfection, Immunoprecipitation, SDS Page

Journal: International Journal of Molecular Sciences

Article Title: HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma

doi: 10.3390/ijms22031341

Figure Lengend Snippet: Working model for HDAC6 inhibitor and PI for overcoming BTZ resistance of MM. HDAC6 inhibition by A452 synergize with BTZ or CFZ to inhibit the activation of NF-κB and STAT3, resulting in decreased expressions of LMP2 and LMP7. Additionally, combination treatment of A452 and BTZ or CFZ synergistically inactivates the AKT and ERK MAPK pathways. Combining A452 with BTZ or CFZ leads to synergistic cancer cell growth inhibition and viability decreases. This combination induces apoptosis and enhances PI sensitivity in the BTZ-resistant MM cells.

Article Snippet: Antibodies against AKT (sc-8312), p-AKT (sc-7985-R), Bak (sc-832), ERK (sc-03-G), HDAC6 (sc-11420), LMP2 (sc-514345), p65 (sc-8008), STAT3 (sc-482), and α-tubulin (sc-32293) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

Techniques: Inhibition, Activation Assay